Company Overview of Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company’s lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute. Syndax Pharmaceuticals, Inc. was founded ...
400 Totten Pond Road
Waltham, MA 02451
Founded in 2005
Key Executives for Syndax Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Co-Founder and Chief Technology Officer
Compensation as of Fiscal Year 2014.
Syndax Pharmaceuticals, Inc. Key Developments
Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® in Lung Cancer and Melanoma
Mar 31 15
Syndax Pharmaceuticals, Inc. and Merck announced that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax’s entinostat, an investigational epigenetic therapy, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States. The Phase 1b/2 study will evaluate this novel combination regimen in patients with either advanced non-small cell lung cancer (NSCLC) or melanoma. The study is expected to begin enrolling patients in the second half of 2015. The financial terms and additional details of the agreement between Syndax and Merck, through a subsidiary, were not disclosed. The agreement includes a provision where the parties may extend the collaboration to include a potential Phase 3 clinical trial. The planned Phase 1b/2 multicenter, open-label clinical trial will be conducted in two parts. The Phase 1b portion is designed to determine the safety and tolerability of entinostat in combination with KEYTRUDA. The Phase 2 portion is designed to evaluate the efficacy of entinostat combined with KEYTRUDA in patients with advanced NSCLC and melanoma.
Syndax Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:30 PM
Feb 26 15
Syndax Pharmaceuticals, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 03:30 PM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Arlene M. Morris, Chief Executive Officer, President and Director.
Syndax Pharmaceuticals, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
Syndax Pharmaceuticals, Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 7, 2015
September 18, 2014